Superior Planning, LLC’s Monte Rosa Therapeutics GLUE Stock Holding History

Superior Planning, LLC’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$131	Buy	+11	New	+$189	﹤0.01%	2066

Other funds holding GLUE

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Superior Planning, LLC's GLUE Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Monte Rosa Therapeutics (GLUE) in Q3 2026: 11 shares worth $131. The stake represents ﹤0.01% of the portfolio and ranks #2066 among its holdings.

89 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

Superior Planning, LLC held 11 shares of Monte Rosa Therapeutics worth $131 as of Q3 2026.
Monte Rosa Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Monte Rosa Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #2066 holding.
89 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.